Patients' perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy

Thorax. 2023 Jul;78(7):721-725. doi: 10.1136/thorax-2022-219490. Epub 2023 May 4.

Abstract

The value placed by patients and their caregivers on the components of composite outcomes in pulmonary arterial hypertension (PAH) remains unknown. We surveyed the importance of these outcomes from a patients' and caregivers' perspective, with participants (n=335, including 257 patients with PAH) rating individual components defining clinical worsening in PAH trials as of critical, major, mild-to-moderate or minor importance. Most outcomes were considered of major or mild-to-moderate importance to patients. Death was the only outcome considered of critical importance. Perceptions of clinical outcomes varied between patients and caregivers. Integrating patients' perception in the elaboration of clinical trials is essential.

Keywords: Clinical Epidemiology; Primary Pulmonary Hypertension.

MeSH terms

  • Clinical Trials as Topic
  • Humans
  • Pulmonary Arterial Hypertension* / drug therapy